^
BIOMARKER:

TMB-H

i
Other names: TMB | Tumor Mutational Burden
Related biomarkers:
TMB-H
Solid Tumor
pembrolizumab
Sensitive: A1 - Approval
TMB-H
Peritoneal Cancer
pembrolizumab
Sensitive: A2 - Guideline
TMB-H
Gastric Cancer
pembrolizumab
Sensitive: A2 - Guideline
TMB-H
Testicular Seminoma
TIP
Sensitive: A2 - Guideline
TMB-H
Sarcoma
pembrolizumab
Sensitive: A2 - Guideline
TMB-H
Thyroid Gland Hurthle Cell Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
TMB-H
Chordoma
pembrolizumab
Sensitive: A2 - Guideline
TMB-H
Germ Cell Tumors
pembrolizumab
Sensitive: A2 - Guideline
TMB-H
Thyroid Gland Follicular Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
TMB-H
Thyroid Gland Medullary Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
TMB-H
Endometrial Cancer
pembrolizumab
Sensitive: A2 - Guideline
TMB-H
Cervical Cancer
pembrolizumab
Sensitive: A2 - Guideline
TMB-H
Thyroid Gland Papillary Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
TMB-H
NSCLC
nivolumab + ipilimumab
Sensitive: A2 - Guideline
TMB-H
Breast Cancer
pembrolizumab
Sensitive: A2 - Guideline
TMB-H
Melanoma
nivolumab + ipilimumab
Sensitive: A2 - Guideline
TMB-H
Ewing Sarcoma
pembrolizumab
Sensitive: A2 - Guideline
TMB-H
Osteosarcoma
pembrolizumab
Sensitive: A2 - Guideline
TMB-H
Thyroid Gland Anaplastic Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
TMB-H
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: A2 - Guideline
TMB-H
Esophageal Cancer
pembrolizumab
Sensitive: A2 - Guideline
TMB-H
Ovarian Cancer
pembrolizumab
Sensitive: A2 - Guideline
TMB-H
Fallopian Tube Cancer
pembrolizumab
Sensitive: A2 - Guideline
TMB-H
Neuroendocrine Tumor
pembrolizumab
Sensitive: A2 - Guideline
TMB-H
Testicular Cancer
pembrolizumab
Sensitive: A2 - Guideline
TMB-H
Vulvar Cancer
pembrolizumab
Sensitive: A2 - Guideline
TMB-H
Prostate Cancer
pembrolizumab
Sensitive: A2 - Guideline
TMB-H
NSCLC
atezolizumab
Sensitive: B - Late Trials
TMB-H
NSCLC
nivolumab
Sensitive: B - Late Trials
TMB-H
Urothelial Cancer
durvalumab + CP-675206
Sensitive: B - Late Trials
TMB-H
Melanoma
pembrolizumab
Sensitive: B - Late Trials
TMB-H
Melanoma
atezolizumab + cobimetinib
Sensitive: B - Late Trials
TMB-H
Urothelial Cancer
durvalumab
Sensitive: B - Late Trials
TMB-H
Melanoma
vemurafenib + atezolizumab + cobimetinib
Sensitive: B - Late Trials
TMB-H
Pancreatic Cancer
pembrolizumab
Sensitive: B - Late Trials
TMB-H
NSCLC
Immunotherapy
Sensitive: B - Late Trials
TMB-H
Melanoma
ipilimumab
Sensitive: B - Late Trials
TMB-H
SCCHN
durvalumab
Sensitive: B - Late Trials
TMB-H
NSCLC
durvalumab + CP-675206
Sensitive: B - Late Trials
TMB-H
Melanoma
nivolumab
Sensitive: B - Late Trials
TMB-H
SCCHN
pembrolizumab
Sensitive: B - Late Trials
TMB-H
SCCHN
durvalumab + CP-675206
Sensitive: B - Late Trials
TMB-H
Small Cell Lung Cancer
nivolumab + ipilimumab
Sensitive: B - Late Trials
TMB-H
Small Cell Lung Cancer
nivolumab
Sensitive: B - Late Trials
TMB-H
Melanoma
PD1 inhibitor
Sensitive: B - Late Trials
TMB-H
Pancreatic Cancer
PD1 inhibitor
Sensitive: B - Late Trials
TMB-H
Triple Negative Breast Cancer
pembrolizumab
Sensitive: C1 - Off-label
TMB-H
NSCLC
pembrolizumab
Sensitive: C1 - Off-label
TMB-H
Squamous Cell Skin Cancer
pembrolizumab
Sensitive: C1 - Off-label
TMB-H
CRC
pembrolizumab
Sensitive: C1 - Off-label
TMB-H
Bladder Cancer
pembrolizumab
Sensitive: C1 - Off-label
TMB-H
Penile Cancer
pembrolizumab
Sensitive: C1 - Off-label
TMB-H
Pancreatic Adenocarcinoma
pembrolizumab
Sensitive: C1 - Off-label
TMB-H
Urothelial Cancer
pembrolizumab
Sensitive: C1 - Off-label
TMB-H
Gastric Cancer
toripalimab
Sensitive: C2 – Inclusion Criteria
TMB-H
Prostate Cancer
nivolumab + ipilimumab
Sensitive: C2 – Inclusion Criteria
TMB-H
Prostate Cancer
nivolumab
Sensitive: C2 – Inclusion Criteria
TMB-H
Solid Tumor
nivolumab + ipilimumab
Sensitive: C2 – Inclusion Criteria
TMB-H
Solid Tumor
atezolizumab
Sensitive: C2 – Inclusion Criteria
TMB-H
Gastric Cancer
sintilimab
Sensitive: C2 – Inclusion Criteria
TMB-H
NSCLC
sintilimab
Sensitive: C2 – Inclusion Criteria
TMB-H
NSCLC
PD-L1 inhibitor
Sensitive: C3 – Early Trials
TMB-H
Urothelial Cancer
atezolizumab
Sensitive: C3 – Early Trials
TMB-H
Neuroendocrine Tumor
toripalimab
Sensitive: C3 – Early Trials
TMB-H
Triple Negative Breast Cancer
atezolizumab
Sensitive: C3 – Early Trials
TMB-H
NSCLC
CTLA4 inhibitor
Sensitive: C3 – Early Trials
TMB-H
Solid Tumor
Immunotherapy
Sensitive: C3 – Early Trials
TMB-H
SCCHN
PD1 inhibitor
Sensitive: C3 – Early Trials
TMB-H
MDS
Immunotherapy
Sensitive: C3 – Early Trials
TMB-H
Prostate Cancer
PD1 inhibitor
Sensitive: C3 – Early Trials
TMB-H
CRC
Immunotherapy
Sensitive: C3 – Early Trials
TMB-H
Prostate Cancer
Immunotherapy
Sensitive: C3 – Early Trials
TMB-H
BCC
Immunotherapy
Sensitive: C3 – Early Trials
TMB-H
GBM
Immunotherapy
Sensitive: C3 – Early Trials
TMB-H
Bladder Cancer
Immunotherapy
Sensitive: C3 – Early Trials
TMB-H
Melanoma
Immunotherapy
Sensitive: C3 – Early Trials
TMB-H
Breast Cancer
Immunotherapy
Sensitive: C3 – Early Trials
TMB-H
Endometrial Cancer
AB122
Sensitive: C3 – Early Trials
TMB-H
NSCLC
PF-06801591
Sensitive: C3 – Early Trials
TMB-H
Urothelial Cancer
durvalumab + ABSK-091
Sensitive: C3 – Early Trials
TMB-H
Melanoma
atezolizumab
Sensitive: C3 – Early Trials
TMB-H
Urothelial Cancer
PD-L1 inhibitor
Sensitive: C3 – Early Trials
TMB-H
Urothelial Cancer
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
TMB-H
Urothelial Cancer
nivolumab
Sensitive: C3 – Early Trials
TMB-H
Urothelial Cancer
avelumab
Sensitive: C3 – Early Trials
TMB-H
Esophageal Cancer
camrelizumab
Sensitive: C3 – Early Trials
TMB-H
Urothelial Cancer
ABSK-091
Sensitive: C3 – Early Trials
TMB-H
Thyroid Gland Carcinoma
pembrolizumab + lenvatinib
Sensitive: C3 – Early Trials
TMB-H
Thyroid Gland Anaplastic Carcinoma
pembrolizumab + lenvatinib
Sensitive: C3 – Early Trials
TMB-H
CRC
nivolumab
Sensitive: C3 – Early Trials
TMB-H
Gastric Cancer
PD1 inhibitor
Sensitive: C3 – Early Trials
TMB-H
CRC
PD1 inhibitor
Sensitive: C3 – Early Trials